IL2 and systemic lupus erythematosus: The ratio of TFR cells to TFH cells may change in certain disease states, such as in systemic lupus erythematosus (SLE), where low-dose IL-2 therapy can inhibit TFH cells and expand TFR cells, thereby regulating pathogenic humoral immunity (29).